Therapeutic Efficacy and Safety of Sitagliptin, Dapagliflozin and Lobeglitazone in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Glimepiride and Metformin.

Trial Profile

Therapeutic Efficacy and Safety of Sitagliptin, Dapagliflozin and Lobeglitazone in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Glimepiride and Metformin.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Lobeglitazone (Primary) ; Sitagliptin (Primary) ; Glimepiride/metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Triple3
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
    • 05 Oct 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
    • 09 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top